7.33k followers • 18 symbols Watchlist by Motif Investing
Successful drug approvals by the FDA and innovations in the treatment of cancer could provide relevant stocks a boost.
Curated by Motif Investing
Cancer is a leading cause of death worldwide, and the number of new cases is expected to rise by about 70 percent over the next two decades. In the U.S., more than half a million people die from cancer which claims one of every four deaths, making it the second leading cause of death after heart disease, according to Centers for Disease Control. As more cancer drugs are approved in the U.S. than anywhere else, it is no wonder that it also pays the highest bills for cancer drugs.
Having reached $100 billion in annual sales, the global market for cancer drugs could reach $147 billion by 2018. Meanwhile, the cost per month for a new cancer drug has jumped 40 percent to nearly $6,000, over the past decade. However you look at it, cancer drugs and innovations in the pipeline are creating significant opportunities in the pharmaceutical and biotech sectors.
We identified US-listed stocks and American Depository Receipts of companies that are engaged in activities relevant to this watchlist's theme. We then filtered out companies that have a share price of less than $1.00 or a market capitalization less than $100 million, and excluded illiquid stocks by screening companies for liquidity i.e. average bid-ask spreads, dollar volume traded etc. Finally the proprietary Motif Optimization Engine determined the constituent stocks. Learn more about how we select our watchlists.Who made these selections?
Motif is an online brokerage built on thematic portfolios of up to 30 stocks and ETFs. Founded in 2010 by Hardeep Walia, Motif combines complex proprietary algorithms with skilled advisers to develop these thematic portfolios. Learn more about our team.How are these weighted?
First, we determined each company's percentage of total revenue derived from this watchlist's theme. Second, we applied a pure-play factor to give greater relative weight to companies that derive a higher percentage of their revenue from this theme. Finally, we weighted each company by its market capitalization adjusted for revenue exposure to the theme.
More details on how we build and weight watchlists are available here.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|BMY||Bristol-Myers Squibb Company||61.02||-0.31||-0.51%||4:00 pm GMT-4||9.97M||14.13M||137.53B|
|SGEN||Seattle Genetics, Inc.||160.45||-1.35||-0.83%||4:00 pm GMT-4||727.65k||1.20M||27.92B|
|EXAS||Exact Sciences Corporation||86.69||-3.71||-4.10%||4:00 pm GMT-4||1.55M||1.37M||13.02B|
|BPMC||Blueprint Medicines Corporation||74.45||-0.18||-0.24%||4:00 pm GMT-4||205.66k||544.85k||4.12B|
|FGEN||FibroGen, Inc.||44.2||+2.75||+6.63%||4:00 pm GMT-4||1.15M||689.06k||3.99B|
|INO||Inovio Pharmaceuticals, Inc.||20.22||-0.11||-0.54%||4:00 pm GMT-4||9.75M||35.86M||3.20B|
|MGNX||MacroGenics, Inc.||27.42||-0.02||-0.07%||4:00 pm GMT-4||516.05k||1.45M||1.48B|
|SPPI||Spectrum Pharmaceuticals, Inc.||3.845||-0.07||-1.66%||4:00 pm GMT-4||3.61M||2.30M||546.32M|
|GERN||Geron Corporation||1.68||+0.02||+1.20%||4:00 pm GMT-4||2.98M||4.01M||521.42M|
|PGNX||Progenics Pharmaceuticals, Inc.||4.1||-0.43||-9.39%||4:00 pm GMT-4||34.93M||1.84M||355.05M|
|ARAY||Accuray Incorporated||2.61||+0.02||+0.77%||4:00 pm GMT-4||353.17k||612.53k||236.25M|
|MACK||Merrimack Pharmaceuticals, Inc.||3.37||+0.07||+2.12%||4:00 pm GMT-4||11.11k||25.89k||45.09M|
|FMI||Foundation Medicine, Inc.||-||-||-||6:07 pm GMT-4||-||-||-|
|INSY||INSYS Therapeutics, Inc.||0.2911||-||-||9:37 am GMT-4||-||-||-|
|SCLN||-||-||-||-||6:07 pm GMT-4||-||-||-|
|JUNO||-||-||-||-||6:07 pm GMT-4||-||-||-|
|KITE||-||-||-||-||6:07 pm GMT-4||-||-||-|
With economic data on the lighter side, geopolitics and the passage of the COVID-19 stimulus package in the U.S remain in focus.
By Gina Lee
It’s a busy week ahead, with economic data, monetary policy, U.S foreign policy, and the path of the U.S stimulus package to drive the markets.